Celldex Reports Second Quarter 2014 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Celldex Therapeutics (CLDX) Reports In-Line Q2 EPS
August 7, 2014 7:53 AM EDTCelldex Therapeutics (NASDAQ: CLDX) reported Q2 EPS of ($0.32), in-line with the analyst estimate of ($0.32). Revenue for the quarter came in at $592 thousand versus the consensus estimate of $340 thousand.
For earnings history and earnings-related data on Celldex Therapeutics (CLDX) click here.
... More